University of Pittsburgh

The Uab Research Foundation

University of Oregon

University College Cardiff Consultants Limited

Morehouse School of Medicine

Francisco Jose Schopfer

Bruce A Freeman

Bruce Branchaud

Yuqing E Chen

Paul Baker

Valerie O'Donnell

Marco Fazzari

Carola Neumann

Nicholas Khoo

Steven Woodcock

A method comprising co-administering to a subject having cancer, suspected of having cancer, or at risk of developing cancer:

Electrophiles and electrophile pro-drugs as RAD51 inhibitors

Compounds of formula I and their metabolites are potent mediators of an inflammatory response: where a, b, c, d, e, f, V, W, X, Y, R, R, R, R, R, and Rare defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.

Fatty acids as anti-inflammatory agents

Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include dicarboxylic acid compounds containing electron withdrawing groups, alkyl esters of dicarboxylic acids containing electron withdrawing groups, or compounds of Formulae I to X. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.

Prevention, treatment and reversal of disease using therapeutically effective amounts of dicarboxylic acid compounds

Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include reversible nitroxide derivatives of nitroalkenes. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.

Reversible nitroxide derivatives of nitroalkenes that mediate nitrosating and alkylating reactions

Nitro oleic acid and related metabolites are agonists of PPAR-&#x3b3;. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-&#x3b3;, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-&#x3b3;.

Nitrated-fatty acids modulation of type II diabetes

Compounds of formula I and their metabolites are potent mediators of an inflammatory response: where a, b, c, d, e, f, V, W, X, Y, R, R, R, R, and Rare defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.

Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include thiolated nitro fatty acids. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.

Reversibly protected thiolated electrophilic fatty acids as prodrugs

Described herein are nitrated lipids and methods of making and using the nitrated lipids.

Growing community of inventors

Pittsburgh, PA, United States of America

Francisco Jose Schopfer